Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...